Bayer Highlights Cell and Gene Therapy Commitment with US$4 B Asklepios Buyout
By Ashish Tripathi & Michelle Liu
Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)
Published: 18 Dec-2020
DOI: 10.3833/pdr.v2020.i12.2581 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a move to bolster its cell and gene therapy portfolio, Bayer has acquired Asklepios BioPharmaceuticals (AskBio), a company focused on the treatment of neuromuscular and cardiovascular system diseases with gene therapy...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS